Abstract
The “amyloid cascade hypothesis,” linking self-assembly of the amyloid-β protein (Aβ) to the pathogenesis of Alzheimer's disease, has led to the emergence of inhibition of Aβ self-assembly as a prime therapeutic strategy for this currently unpreventable and devastating disease. The complexity of Aβ self-assembly, which involves multiple reaction intermediates related by nonlinear and interconnected nucleation and growth mechanisms, provides multiple points for inhibitor intervention. Although a number of small-molecule inhibitors of Aβ self-assembly have been identified, little insight has been garnered concerning the point at which these inhibitors intervene within the Aβ assembly process. In the current study, a julolidine derivative is identified as an inhibitor of Aβ self-assembly. To gain insight into the mechanistic action of this inhibitor, the inhibition of fibril formation from monomeric protein is assessed quantitatively and compared with the inhibition of two distinct mechanisms of growth for soluble Aβ aggregation intermediates. This compound is observed to significantly inhibit soluble aggregate growth by lateral association while having little effect on soluble aggregate elongation via monomer addition. In addition, inhibition of soluble Aβ aggregate association exhibits an IC50 with a somewhat lower stoichiometric ratio than the IC50 determined for inhibition of fibril formation from monomeric Aβ. This quantitative comparison of inhibition within multiple Aβ self-assembly assays suggests that this compound binds the lateral surface of on-pathway intermediates exhibiting a range of sizes to prevent their association with other aggregates, which is required for further assembly into mature fibrils.
Footnotes
-
This work was supported by the National Science Foundation Early Career Development Program [Grant CBET-0644826]; a Graduate Fellowship from the Alfred P. Sloan Foundation Minority Ph.D. Program; a Graduate Fellowship from the South East Alliance for Graduate Education and the Professoriate; and a Graduate Research Fellowship from the University of South Carolina College of Arts and Sciences.
-
ABBREVIATIONS: AD, Alzheimer's disease; Aβ, amyloid-β protein; DLS, dynamic light scattering; DMF, dimethylformamide; DMSO, dimethylsulfoxide; HFIP, hexafluoroisopropanol; RH, hydrodynamic radius; TEM, transmission electron microscopy; ThT, thioflavin T; SEC, size-exclusion chromatography.
-
↵1 Current affiliation: Eastman Chemical Company, Kingsport, Tennessee.
- Accepted May 27, 2009.
- Received February 6, 2009.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|